Ana Maiques Presents Neuroelectrics at LSI Europe '23

Transcription

Ana Maiques  0:05  
I'm the CEO and founder of Neuroelectrics and I want to welcome you to Barcelona, which is my hometown. So I usually live in Boston where I spend most of my time. So I'm thrilled that for once you all are coming this way. So thanks for being in Barcelona, and I hope you enjoy our wonderful city. Can you put the volume up, please a little bit? So how does the song make you feel? Pretty sad, right? What about if I tell you this is the sound of a brain suffering from depression. So when your brain suffers from depression, that is what we call frontal symmetry. The right hemisphere and the left hemisphere are not creating the right brainwaves, and is creating the distorted sound that I'm trying to put with sound. Right? So this is the sound of a sick brain, in depression. So at Neuroelectrics, we have been obsessed for the last 10 years to unlock how the brain works from an electric perspective. In the Roman times in the Egyptian times, did you know that Egyptians took electric fish from the water and put them on their heads to deal with pain? So the concept of electricity in humanity has been there for ages. What about if we can really understand how the brain works from an electric perspective? So we have been obsessed with this technology called transcranial current stimulation, many of you know it as tDCS. But it's a neuro modulation modality that injects very low voltage, current non invasively in the brain. And we have been also analyzing 1000s of EEG during the last 10 years, which you are more familiar with. So as a conclusion, we develop this wonderful cap. And I think that's the only reason why they call me to conferences, because they want me to wear it. And people don't even recognize me, if I don't wear it. Sometimes I wear the cap and they say, Oh, it's you. Like you know, without the cap, I'm no one anymore. So this is the technology that we have developed a Neuroelectrics is a non invasive, Edi and transcranial current stimulation device. As you can see, it's portable is wearable, I have 32 leads, and we can read and write the brain non invasively. So what are we going to do with it? Why is this so amazing? One of the things is that we can take an I don't think this video is going to work. Okay, we can take this technology to help patients that are suffering from different diseases. So we started in Boston, our first clinical trial is an ID FDA in epilepsy, and then a second it in depression, I'm going to tell you a little bit more about the data we have collected. So Epilepsy is a pretty devastating disease. 60 million patients in the world 1/3 Don't respond to medication. And your alternative is surgery. So what we did with the help of Dr. Rottenburg, at Boston Children's is we took these patients, which have a focal seizure location, and we stimulated 10 days, 20 minutes every day with this cap. So we decided where the focus was coming from, created the protocol and give them 20 minutes of transcranial direct stimulation during 10 days, we compare baseline of 12 weeks with follow up period. And with this, we managed to reduce seizures 47% average. I repeat 10 days of stimulation, noninvasive will reduce seizures 47%. So the results were so good that the FDA granted us breakthrough designation. And through a lot of hard hard work. And I'll tell you more about it, we manage to raise $20 million from our Boston investors a year and a half ago. And now we are executing 190 patients between the US and Europe in the first pivotal tDCS trial in the United States. So if we succeed, and we hope to have the data at the end of next year, we will become the first company in the world to go through the FDA with this new neuromodulation modality. I think this is the beauty of an entrapreneur you think of something in Barcelona years ago, you scale up to Boston, and now you're at the footsteps of becoming a new therapy that will be transformational to many, many patients. So wish me luck in and my team to finish this trial in time next year. And to really grant these FDA clearance, but we will not stop there. We think that the future of this technology is taken at home. So during the pandemic we asked the FDA, all these patients suffering from depression can not go to the hospital to receive TMS or other neuromodulation, will you allow us to send devices home to patients? And this was a great opportunity of the pandemic. So the FDA say yes, so we send patients devices. These were major depressive disorder patients, and we stimulate them during 37 days at home, self administer, 30 minutes every day. So this was a major endeavor, most of our patients were in Florida and Texas, and and another state I don't remember. But we stimulate in those 37 days, they all self administer, which was amazing. And the primary endpoint was Madras. We were so impressed with the data readout. So as you can see, in these first 33 patients data, the patient responded super well to stimulation. And we are so encouraged that now we are raising our series B, our investors are putting most of it already. But if you're interested, let me know, to turn this into a pivotal 300 patient studies, I think that the beauty is that depression, it will be whole at home. So we'll be sending patients this gear. And I think this will become a transformational therapy for so many patients in mental health. So there that our pilot, and not only we have these amazing technology and these clinical trials, but we are working on the future, we believe in the future, we'll build a neural twin or digital replica of your brain on the cloud. So we have 25 people in the company, only doing brain models. My co founder is a physicist and mathematician. And we believe in computational neuroscience to personalized therapies. This hasn't been done before with the brain. So what we are taking these your brain with an MRI, and building a neural twin of your brain with you know, the physicals of your brain, your scalp, your conductivity is different from than that from Rosa or Rafael. And then your electrophysiology. How does your brain perform electrically, with this computational model of your brain, we can personalize therapies in the cloud in ways you cannot imagine before. So instead of prescribing a stimulation session or a drug, you can play it on the cloud. So this is a major endeavor. And thanks to the commission and grants that we have, we are building neuro twins in epilepsy in Alzheimer's in depression. And I think this is going to be the future of medicine in general. So just to finalize, I'm a very proud women CEO entrepreneur with a lot of awards. I have a Goldman Sachs award and Yass from Goldman Sachs was here yesterday, she nominated me. I've been so welcoming the US by a lot of networks. So I really want to thank the welcoming of the US to an entrapreneur coming from Europe, and an amazing advisory board. And most of all, I have almost 100 People here in Barcelona and the US working restlessly row, Sandra Fowler here from my team, more than 40% women on board engineers, so I really encourage you to let your daughters be excited about STEM. I think we need more women on board. And let me tell you while you're in Barcelona, my team and myself will keep on working restlessly until we really can help those patients and provide this neuromodulation approach. And I hope that all the brains will sound like this not sad anymore, but with a happy music. Thank you very much.